Skip to main content
Top
Published in: Cancer and Metastasis Reviews 2/2015

01-06-2015

Lung cancer and metastasis: new opportunities and challenges

Authors: Xiangdong Wang, Alex A. Adjei

Published in: Cancer and Metastasis Reviews | Issue 2/2015

Login to get access

Abstract

Lung cancer continues to attract special attention since the real number of lung cancer mortality and incidence in 2014 was definitely higher than those estimated numbers according to the report from World Health Organization. The present special issue highly focuses on advanced discovery and development of lung cancer and metastasis and discusses about potential opportunities and challenges to be faced. The present issue explores clinical applications of cancer immunotherapies, gene therapies, radiotherapies, or target-oriented therapies. A new and novel methodology can be used to identify differential interactions of driver genes, cancer-predictive genes, subtype-specific genes, or disease-exclusive genes or gene pairs from imbalanced or heterogeneous datasets. We also demonstrate the importance of lung cancer-specific gene mutations, epigenetics, gene sequencing, heterogeneity, or biomarker discovery. Clinical bioinformatics is emphasized as a critical tool and merging science. Novel therapies are designed and expected on basis of oncogenic molecular aberrations in lung cancer.
Literature
1.
go back to reference Smith, R. A., Manassaram-Baptiste, D., Brooks, D., Doroshenk, M., Fedewa, S., Saslow, D., Brawley, O. W., & Wender, R. (2015). Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians, 65(1), 30–54. doi:10.3322/caac.21261. Smith, R. A., Manassaram-Baptiste, D., Brooks, D., Doroshenk, M., Fedewa, S., Saslow, D., Brawley, O. W., & Wender, R. (2015). Cancer screening in the United States, 2015: A review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians, 65(1), 30–54. doi:10.​3322/​caac.​21261.
2.
go back to reference Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. doi:10.1002/ijc.29210.CrossRef Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136(5), E359–E386. doi:10.​1002/​ijc.​29210.CrossRef
4.
go back to reference Salama, J. K., & Schild S. E. (2015). Radiation therapy for oligometastatic non-small cell lung cancer. Cancer & Metastasis Review. Salama, J. K., & Schild S. E. (2015). Radiation therapy for oligometastatic non-small cell lung cancer. Cancer & Metastasis Review.
6.
go back to reference de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., et al. (2014). Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science, 346(6206), 251–256. doi:10.1126/science.1253462.PubMedCrossRef de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., et al. (2014). Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science, 346(6206), 251–256. doi:10.​1126/​science.​1253462.PubMedCrossRef
7.
go back to reference Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., et al. (2014). Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 346(6206), 256–259. doi:10.1126/science.1256930.PubMedCrossRef Zhang, J., Fujimoto, J., Zhang, J., Wedge, D. C., Song, X., Zhang, J., et al. (2014). Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science, 346(6206), 256–259. doi:10.​1126/​science.​1256930.PubMedCrossRef
8.
go back to reference Wu, D. J., Wang, X. D. (2015). Application of clinical bioinformatics in lung cancer-specific biomarkers. Cancer & Metastasis Review. Wu, D. J., Wang, X. D. (2015). Application of clinical bioinformatics in lung cancer-specific biomarkers. Cancer & Metastasis Review.
9.
go back to reference Mehta, A., Romero-Olmedo, A. J., Dobersch S., Barreto G. (2015). Significance of epigenetics in lung cancer diagnosis and therapy. Cancer & Metastasis Review. Mehta, A., Romero-Olmedo, A. J., Dobersch S., Barreto G. (2015). Significance of epigenetics in lung cancer diagnosis and therapy. Cancer & Metastasis Review.
11.
go back to reference Landesman-Milo, D., Ramishetti, S., Peer, D. (2015). Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer & Metastasis Review. Landesman-Milo, D., Ramishetti, S., Peer, D. (2015). Nanomedicine as an emerging platform for metastatic lung cancer therapy. Cancer & Metastasis Review.
Metadata
Title
Lung cancer and metastasis: new opportunities and challenges
Authors
Xiangdong Wang
Alex A. Adjei
Publication date
01-06-2015
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 2/2015
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-015-9562-4

Other articles of this Issue 2/2015

Cancer and Metastasis Reviews 2/2015 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine